A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseases.

Callum Ah Docherty, Anuruddika J Fernando,Sarah Rosli,Maggie Lam,Roland E Dolle, Manuel A Navia,Ronald Farquhar, Danny La France,Michelle D Tate,Christopher K Murphy,Adriano G Rossi,Ashley Mansell

Clinical & translational immunology（2023）

引用 4|浏览5

暂无评分

摘要

ADS032 is the first described dual inflammasome inhibitor and a potential therapeutic to treat both NLRP1- and NLRP3-associated inflammatory diseases and also constitutes a novel tool that allows examination of the role of NLRP1 in human disease.

查看译文

关键词

inflammatory diseases,inhibitor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要